Allurion Technologies (Allurion Technologies) Retained Earnings : $-207.21 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Allurion Technologies Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Allurion Technologies's retained earnings for the quarter that ended in Mar. 2024 was $-207.21 Mil.

Allurion Technologies's quarterly retained earnings declined from Sep. 2023 ($-193.62 Mil) to Dec. 2023 ($-212.80 Mil) but then increased from Dec. 2023 ($-212.80 Mil) to Mar. 2024 ($-207.21 Mil).

Allurion Technologies's annual retained earnings declined from Dec. 2021 ($-94.45 Mil) to Dec. 2022 ($-132.19 Mil) and declined from Dec. 2022 ($-132.19 Mil) to Dec. 2023 ($-212.80 Mil).

Allurion Technologies Retained Earnings Historical Data

The historical data trend for Allurion Technologies's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allurion Technologies Retained Earnings Chart

Allurion Technologies Annual Data

Trend

Dec21

Dec22

Dec23

Retained Earnings

-94.45

-132.19

-212.80

Allurion Technologies Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial					-149.99	-171.99	-193.62	-212.80	-207.21

Allurion Technologies Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Allurion Technologies (NYSE:ALUR) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Allurion Technologies (Allurion Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Allurion Technologies Inc (NYSE:ALUR) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Huron Drive, Natick, MA, USA, 01760

Website

Allurion Technologies Inc is a leading medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Executives

Omar Ishrak	director	710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Nicholas Sheridan Lewin	director	3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Krishna K. Gupta	director, 10 percent owner	307 HARVARD ST, CAMBRIDGE MA 02139
Christopher J Geberth	officer: Chief Financial Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Michael R Davin	director	C/O CYNOSURE, INC., 5 CARLISLE ROAD, WESTFORD MA 01886
Larson Douglas Hudson	director	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Benoit Chardon	officer: Chief Commercial Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Shantanu Gaur	director, officer: Chief Executive Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Ram Chuttani	officer: Chief Medical Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760